Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
Ben Creelan, Tammie C. Yeh, Sang-We Kim, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 2, pp. 383-390
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Alissa J. Cooper, Lecia V. Sequist, W. Marston Linehan
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 8, pp. 499-514
Open Access | Times Cited: 309
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 51-69
Closed Access | Times Cited: 146
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
Kenneth K.W. To, Winnie Fong, William C. Cho
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 111
Incidence and risk factors of drug‐induced liver injury
Xiaoyun Li, Jieting Tang, Yimin Mao
Liver International (2022) Vol. 42, Iss. 9, pp. 1999-2014
Closed Access | Times Cited: 90
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Itziar Otano, Álvaro C. Ucero, Jon Zugazagoitia, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 143-159
Closed Access | Times Cited: 84
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
Clelia Madeddu, Clelia Donisi, Nicole Liscia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6489-6489
Open Access | Times Cited: 83
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study
Rolof G.P. Gijtenbeek, Ronald Damhuis, Anthonie J. van der Wekken, et al.
The Lancet Regional Health - Europe (2023) Vol. 27, pp. 100592-100592
Open Access | Times Cited: 33
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
Shanshan Chen, Jingyi Tang, Fen Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Natalie I. Vokes, Kelsey Pan, Xiuning Le
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 24
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Julian A. Marin‐Acevedo, Bruna Pellini, ErinMarie O. Kimbrough, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 629-629
Open Access | Times Cited: 23
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
Peter R. Galle, Richard S. Finn, Catherine Mitchell, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e008266-e008266
Open Access | Times Cited: 10
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yu Yuan, Abdalla Adam, Chen Zhao, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 663-663
Open Access | Times Cited: 50
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Tina Cascone, Jared J. Fradette, Monika Pradhan, et al.
Cold Spring Harbor Perspectives in Medicine (2021) Vol. 12, Iss. 5, pp. a037895-a037895
Open Access | Times Cited: 42
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 21
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Ilaria Attili, Antonio Passaro, Carla Corvaja, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102602-102602
Closed Access | Times Cited: 19
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
Ramon Andrade de Mello, Nathália Moisés Neves, Hakaru Tadokoro, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3543-3543
Open Access | Times Cited: 42
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Ramaswamy Govindan, Charu Aggarwal, Scott Antonia, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e003956-e003956
Open Access | Times Cited: 26
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Jia Zhong, Hua Bai, Zhijie Wang, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 1, pp. 18-42
Closed Access | Times Cited: 14
EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
Huayan Huang, Xiaokuan Zhu, Yongfeng Yu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
Anjali Kalra, Sawsan Rashdan
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Organometallic gold(I) and gold(III) complexes for lung cancer treatment
Juzheng Zhang, Yanping Li, Ronghao Fang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 19
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Danielle Brazel, Gianna Kroening, Misako Nagasaka
BioDrugs (2022) Vol. 36, Iss. 6, pp. 717-729
Open Access | Times Cited: 18
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
Chun­yan Shi, Yan Wang, Jianxin Xue, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives
Miriam Dorta-Suárez, Maria J. de Miguel, Óscar Amor-Carro, et al.
Cancer Treatment Reviews (2023) Vol. 124, pp. 102671-102671
Closed Access | Times Cited: 10
Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
Elodie Long‐Mira, Christophe Bontoux, Guylène Rignol, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1034-1034
Open Access
Page 1 - Next Page

Scroll to top